<VariationArchive VariationID="568436" VariationName="NM_000020.3(ACVRL1):c.145del (p.Ala49fs)" VariationType="Deletion" Accession="VCV000568436" Version="6" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-05-01" DateCreated="2018-10-10" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="566902" VariationID="568436">
      <GeneList>
        <Gene Symbol="ACVRL1" FullName="activin A receptor like type 1" GeneID="94" HGNC_ID="HGNC:175" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q13.13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="51906944" stop="51923361" display_start="51906944" display_stop="51923361" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="52301201" stop="52317144" display_start="52301201" display_stop="52317144" Strand="+" />
          </Location>
          <OMIM>601284</OMIM>
          <Haploinsufficiency last_evaluated="2016-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ACVRL1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2016-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ACVRL1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000020.3(ACVRL1):c.145del (p.Ala49fs)</Name>
      <CanonicalSPDI>NC_000012.12:51913176:GGGGGG:GGGGG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>12q13.13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="51913177" stop="51913177" display_start="51913177" display_stop="51913177" variantLength="1" positionVCF="51913176" referenceAlleleVCF="CG" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="52306961" stop="52306961" display_start="52306961" display_stop="52306961" variantLength="1" positionVCF="52306960" referenceAlleleVCF="CG" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>A49fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.52306966del" Assembly="GRCh37">
            <Expression>NC_000012.11:g.52306966del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.51913182del" Assembly="GRCh38">
            <Expression>NC_000012.12:g.51913182del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009549.1" sequenceAccession="NG_009549" sequenceVersion="1" change="g.10765del">
            <Expression>NG_009549.1:g.10765del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000020.3" sequenceAccession="NM_000020" sequenceVersion="3" change="c.145del" MANESelect="true">
            <Expression>NM_000020.3:c.145del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000011.2" sequenceAccession="NP_000011" sequenceVersion="2" change="p.Ala49fs">
            <Expression>NP_000011.2:p.Ala49fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077401.2" sequenceAccession="NM_001077401" sequenceVersion="2" change="c.145del">
            <Expression>NM_001077401.2:c.145del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001070869.1" sequenceAccession="NP_001070869" sequenceVersion="1" change="p.Ala49fs">
            <Expression>NP_001070869.1:p.Ala49fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_543" sequenceAccession="LRG_543">
            <Expression>LRG_543:g.10765del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000020.2" sequenceAccession="NM_000020" sequenceVersion="2" change="c.145delG">
            <Expression>NM_000020.2:c.145delG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="863223415" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000020.3(ACVRL1):c.145del (p.Ala49fs) AND Telangiectasia, hereditary hemorrhagic, type 2" Accession="RCV000688794" Version="4">
        <ClassifiedConditionList TraitSetID="2259">
          <ClassifiedCondition DB="MedGen" ID="C1838163">Telangiectasia, hereditary hemorrhagic, type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-11-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000020.3(ACVRL1):c.145del (p.Ala49fs) AND Cardiovascular phenotype" Accession="RCV002388215" Version="2">
        <ClassifiedConditionList TraitSetID="32616">
          <ClassifiedCondition DB="MedGen" ID="CN230736">Cardiovascular phenotype</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-06-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-11-20" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2018-10-10" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12114496</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15879500</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="32616" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="33389" Type="Finding">
              <Name>
                <ElementValue Type="Preferred">Cardiovascular phenotype</ElementValue>
              </Name>
              <XRef ID="CN230736" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2259" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3671" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Osler Weber Rendu syndrome type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Telangiectasia, hereditary hemorrhagic, type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Telangiectasia, hereditary hemorrhagic, type 2</ElementValue>
                <XRef ID="MONDO:0010880" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HHT2</ElementValue>
                <XRef Type="MIM" ID="600376" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ORW2</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9901" />
                <XRef ID="9901" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000511258" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500010" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000241591" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509788" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515716" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512240" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528531" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515719" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528884" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. The most common clinical manifestation is spontaneous and recurrent nosebleeds (epistaxis) beginning on average at age 12 years. Telangiectases (small AVMs) are characteristically found on the lips, tongue, buccal and gastrointestinal (GI) mucosa, face, and fingers. The appearance of telangiectases is generally later than epistaxis but may be during childhood. Large AVMs occur most often in the lungs, liver, or brain; complications from bleeding or shunting may be sudden and catastrophic. A minority of individuals with HHT have GI bleeding, which is rarely seen before age 50 years.</Attribute>
                <XRef ID="NBK1351" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301525</ID>
                <ID Source="BookShelf">NBK1351</ID>
              </Citation>
              <Citation Type="general" Abbrev="HHT Foundation Int'l, 2011">
                <ID Source="PubMed">19553198</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Shovlin et al., 2000">
                <ID Source="PubMed">10751092</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="HHT Foundation Int'l, 2020">
                <ID Source="PubMed">32894695</ID>
              </Citation>
              <XRef ID="774" DB="Orphanet" />
              <XRef ID="C1838163" DB="MedGen" />
              <XRef ID="MONDO:0010880" DB="MONDO" />
              <XRef Type="MIM" ID="600376" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1588612" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="3759994|MedGen:C1838163" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000816418" DateUpdated="2024-02-14" DateCreated="2018-10-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-11-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12114496</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15879500</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 568436). This premature translational stop signal has been observed in individuals with hereditary hemorrhagic telangiectasia (PMID: 12114496). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ala49Profs*5) in the ACVRL1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ACVRL1 are known to be pathogenic (PMID: 15879500).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ACVRL1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000012.11:g.52306961del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1838163" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB4474525</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5186126" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2022-11-29">
        <ClinVarSubmissionID localKey="a63804|MedGen:CN230736" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002697148" DateUpdated="2024-05-01" DateCreated="2022-11-29" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-06-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12114496</ID>
          </Citation>
          <Comment>The c.145delG pathogenic mutation, located in coding exon 2 of the ACVRL1 gene, results from a deletion of one nucleotide at nucleotide position 145, causing a translational frameshift with a predicted alternate stop codon (p.A49Pfs*5). This pathogenic mutation was identified in an individual presenting with epistaxis and telangienctasias (Olivieri C, J. Med. Genet. 2002 Jul; 39(7):E39). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ACVRL1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000020.2:c.145delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Finding">
          <Trait Type="Finding">
            <XRef DB="MedGen" ID="CN230736" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5186126" TraitType="Finding" MappingType="XRef" MappingValue="CN230736" MappingRef="MedGen">
        <MedGen CUI="CN230736" Name="Cardiovascular phenotype" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1588612" TraitType="Disease" MappingType="XRef" MappingValue="C1838163" MappingRef="MedGen">
        <MedGen CUI="C1838163" Name="Telangiectasia, hereditary hemorrhagic, type 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

